1 completed. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Porphyria, Variegate: new trials by email Literature Review of Porphyria, Variegate trials Research Report on Porphyria, Variegate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) Givosiran, Placebo - Acute Hepatic Porphyria, Acute Intermittent Porphyria | Phase 3 | Completed | Alnylam Pharmaceuticals | 94 | 2017-11-16 | 2024-04-22 |
Coproporphyria, Hereditary (1) · Porphyria, Acute Intermittent (1) · Porphyrias (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Genetic Diseases, Inborn (1) · Liver Diseases (1) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1) · Porphyrias, Hepatic (1) · Skin Diseases (1) · Skin Diseases, Genetic (1) · Skin and Connective Tissue Diseases (1)
givosiran (1)
Australia (1) · Bulgaria (1) · Canada (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · Poland (1) · South Korea (1) · Spain (1) · Sweden (1)
PMID 32521132, PMID 36028858, PMID 37479139, PMID 38044204, PMID 41388232